Member Posts > A Revolutionary Biotech Breakthrough - Cardiol Therapeutics' Myocarditis Research
Myocarditis: A Silent Threat to Heart Health
Many myocarditis patients remain undiagnosed until symptoms worsen, leading to permanent heart damage, life-threatening arrhythmias, or heart failure. Current treatments are supportive but do not address the underlying inflammation.
How Cardiol Therapeutics is Changing the Landscape
🔬 CardiolRx™ reduces pro-inflammatory cytokines linked to myocarditis.
🔬 Targets myocardial fibrosis, preventing heart tissue damage.
🔬 Clinically tested in the ARCHER Phase II Trial, a placebo-controlled study assessing real-world efficacy.
📌 Clinical Milestone: 100 patients enrolled, results expected early 2025.
🔗 Stay informed on groundbreaking myocarditis research:

#HeartHealth #CardiolTherapeutics #MedicalBreakthroughs